Herborium Group Achieves Double Digit Sales Growth for 10th Consecutive Quarter

The Company in Talks with Major Distributors


Fort Lee, New Jersey, June 25, 2015 (GLOBE NEWSWIRE) -- Herborium® Group, Inc. (OTC Pink: HBRM),  www.Herborium.com, a Botanical Therapeutics® Company and the provider of unique all  botanical medicinal products  (Botanical Therapeutics®) that target dermatological problems such as acne, and other health  and wellness concerns,   reports  that  its sales  for  the Second Quarter of  2015  grew by 10% in comparison to the same period of 2014, and by over 30% for the 6 months period of 2015 in comparison to the same period of 2014.  This marks the 10th consecutive quarter of double digit growth. 

This impressive and sustainable growth over the past 6 months may be attributed to Herborium's very aggressive and innovative Social Media strategy.  In addition, the Social Media Strategy significantly helps to establish the AcnEase® and Herborium brands thereby generating valuable future leads.  AcnEase has been featured by a number of the prominent US and international bloggers including Et Pourqoi Coline, Sandrea26France and Cassandra Bankson.  AcnEase has over 10,000 followers on Facebook and over 100,000 impressions for the past 30 days promotional cycle. In addition, the company is one of the most prominent on Pinterest with a recent campaign generating   95,000 impressions.  The company is also uses Twitter, Tumbler (420 million users) and Instagram (300 million users).

As a result,  the company is presently in advanced talks with two major on- line platforms with both domestic and global reach and is  preparing an AcnEase launch with Dermstore (one of the  major  e -distributors  in the US Beauty) and by nationally acclaimed Bliss Spa.   In addition, the Company is in talks with two major national brick and mortar chain distributors.  These developments should allow the company to surpass the million dollar sales mark and achieve profitability within next 6-9 months

Herborium remains very optimistic about growing its business, sales and product awareness. While recognizing the expenses associated with developing and launching new products and the associated upfront costs Herborium firmly believes   that its growth record combined with the rising interest in Botanical Therapeutics® among consumers, medical professional and medical communities at large, serve as a solid foundation for the company's promising future.      

About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements).  The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.  Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, and www.acnease.com.

Safe Harbor Statement:  This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties.  The Company's actual future results could materially differ from those discussed.   The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.


            

Contact Data